InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

Gold’s Trajectory is Breaking Away from Traditional Correlations

October 1, 2026 — Gold is displaying unusual strength despite a combination of market conditions that would traditionally be expected to weigh heavily on its price. The greenback has strengthened, the Fed remains restrictive, and the 10-year Treasury yield has climbed toward 5.


Digital Finance to Take Center Stage During XRP Seoul Blockchain Week

October 1, 2026 — October is shaping up to be an active month for the XRP ecosystem, with a major industry gathering in South Korea, several network amendments, and Ripple-related events scheduled over the coming weeks. Crypto industry actors like Circle Internet Group Inc.


Floating Power Plants Hold the Potential to Provide Reliable Energy

October 1, 2026 — Power generating stations built onto ships and barges are emerging as a dependable electricity source for islands, harbor towns and crowded cities that have little room to spare. Backers say the vessels sidestep the complaints about space and scenery that dog large solar and wind farms, because they feed a shore-side grid directly from the water.


Health Insurance Has Spiked 78% in the US Since 2011

October 1, 2026 — Surging health insurance costs have compelled even healthcare workers to stop getting coverage not only for themselves but also for their staff at private facilities. Premiums climbed 78% between 2011 and 2024, a JAMA study shows.


Trump Announces Plans to End Biden’s EV Mandate

October 1, 2026 — President Donald Trump is ending the Biden-era electric vehicle mandates, announcing revised mileage standards that he says will make new cars cheaper to buy. Manufacturers, he contends, will respond by building more vehicles in American factories.


InvestorNewsBreaks – Polymath Research Inc. Collaborates With CineCity Studios to Explore Tokenized Film Investment Platform

October 1, 2026 — Polymath, a provider of enterprise-grade infrastructure for regulated digital securities and tokenized financial instruments, announced a collaboration with CineCity Studios to explore development of a technology-enabled investment platform for film and entertainment investors. Under the proposed structure, Polymath would serve as technology partner for a tokenized film investment vehicle, providing infrastructure for digital securities issuance, investor onboarding, compliance workflows, investor management and administration of tokenized interests.


BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

October 1, 2026 — HealthLynked (OTCQB: HLYK), a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care into the HealthLynked mobile application and website, allowing users to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform.


TechMediaBreaks – TruGolf Holdings, Inc. (NASDAQ: TRUG) Announces First TruGolf Range Installation Featuring AI Coach

September 30, 2026 — TruGolf (NASDAQ: TRUG) announced the first installation of its indoor range platform, TruGolf Range, featuring the company’s new TruGolf AI Coach experience at Lucid Golf in New Albany, Indiana. TruGolf Range allows up to five players to practice simultaneously on a single cinematic screen, with each hitting bay providing slow-motion replay of club and ball interaction, ball flight data and integrated AI analysis of swing tendencies.


BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast

September 30, 2026 — Quantum BioPharma (NASDAQ: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast to discuss the company’s Lucid-MS drug candidate, which is advancing to a Phase 2 trial in multiple sclerosis patients, as well as the development and commercial opportunity surrounding unbuzzd(TM). Durkacz said Lucid-MS targets myelin and that the upcoming trial will mark the first time the drug is tested in patients with multiple sclerosis.